<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00133705</url>
  </required_header>
  <id_info>
    <org_study_id>RO1-HD042578-2</org_study_id>
    <nct_id>NCT00133705</nct_id>
  </id_info>
  <brief_title>Trial of Mifepristone for Fibroids</brief_title>
  <official_title>Randomized Control Trial Of Mifepristone for Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine if low-dose mifepristone benefits women with
      symptomatic fibroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is designed to assess the efficacy and tolerability of mifepristone 5 mg given
      daily for 6 months to pre-menopausal women with symptomatic fibroids. The primary study
      outcome will be disease-specific quality of life. Secondary outcome measures include global
      quality of life, pain, bleeding, potential adverse effects, tumor size, and endometrial
      effects. The researchers will also examine a the effect of mifepristone on uterine blood
      flow. Randomization of study subjects will be stratified in order to ensure that equal
      numbers of women with moderate and severe symptoms will be enrolled in the placebo and
      control groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uterine Volume</measure>
    <time_frame>6 months</time_frame>
    <description>Uterine volume is measured in mLs</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Leiomyoma</condition>
  <arm_group>
    <arm_group_label>Mifepristone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mifepristone 5 MG capsule taken once daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inert capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for Mifepristone) capsule of nearly identical color, size, and weight taken once daily by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>Mifepristone 5mg/day by mouth for 6 months</description>
    <arm_group_label>Mifepristone</arm_group_label>
    <other_name>RU486</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inert Capsule</intervention_name>
    <description>sugar pill</description>
    <arm_group_label>Inert capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender: Female

          -  Age: 18 - premenopausal

          -  Have at least moderate symptoms of menorrhagia or pelvic pain/pressure

          -  Have a total uterine volume greater than or equal to 160 cc by ultrasound measurement
             and at least one fibroid that is =&gt; 2.5cm in size

          -  Have a score of equal to or greater than 39 on the Uterine Fibroid Symptom and Quality
             of Life scale

          -  Declined standard treatment options for symptomatic fibroids

          -  Agree to use a double-barrier method (condoms, diaphragms) or other effective
             non-hormonal methods of contraception (abstinence, sterilization) throughout
             participation in the study to prevent pregnancy and to report any exposure to
             pregnancy to the research staff immediately

          -  Willing and able to give informed consent

          -  Willing and able to comply with study requirements

        Exclusion Criteria:

          -  Current or planned pregnancy during the study period

          -  Menopausal, as indicated by follicle stimulating hormone (FSH) level of the reference
             laboratory

          -  Currently breast-feeding

          -  Untreated abnormal pap smear

          -  Presence of conditions other than fibroids contributing to pain and/or bleeding

          -  Hemoglobin &lt; 9.0 mg/dl

          -  Presence of adnexal masses or tenderness indicating further evaluation or surgery

          -  Grade III or IV hydronephrosis by ultrasound

          -  Severe, active mental health disorder

          -  Active substance abuse or dependence

          -  Presence of any contraindication to mifepristone including:

               -  Adrenal insufficiency by history

               -  Sickle cell disease

               -  Active liver disease (liver function tests greater than 1.5 times upper range of
                  normal)

               -  Severe, respiratory disease (P02 saturation&lt; 92%)

               -  Renal disease (serum creatinine &gt; 1.5 mg/dl)

               -  Blood clotting defect. (abnormal PT and PTT)

               -  Thromboembolic disease (history of deep vein thrombosis or pulmonary embolus)

          -  Current or recent (within the past 3 months) use of the following medications:

               -  Oral or systemic corticosteroids

               -  Hormones: estrogens, progestins, oral contraceptives

               -  Danazol, anticoagulants

          -  Herbal or botanical supplements with possible hormonal effects.

          -  Use within the past six months of the gonadotropin releasing hormones (GnRH) analogs
             or Depo-Provera.

          -  Current or planned use during the study of any of the following medications/or
             products:

               -  ketoconazole,

               -  itraconazole,

               -  erythromycin,

               -  grapefruit juice,

               -  rifampin,

               -  St John's Wort,

               -  phenytoin,

               -  phenobarbital, or

               -  carbamazepine
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Fiscella, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester School of Medicine &amp; Dentistry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester School of Medicine &amp; Dentistry</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol. 2005 May-Jun;12(3):227-33.</citation>
    <PMID>15922980</PMID>
  </reference>
  <reference>
    <citation>Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003 Feb;101(2):243-50.</citation>
    <PMID>12576246</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2005</study_first_submitted>
  <study_first_submitted_qc>August 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2005</study_first_posted>
  <results_first_submitted>November 1, 2012</results_first_submitted>
  <results_first_submitted_qc>November 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 30, 2012</results_first_posted>
  <last_update_submitted>February 13, 2014</last_update_submitted>
  <last_update_submitted_qc>February 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Kevin Fiscella</investigator_full_name>
    <investigator_title>Tenured Professor</investigator_title>
  </responsible_party>
  <keyword>A benign tumor derived from smooth uterine muscle tissue.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women were recruited between March 3, 2004 and March 30, 2005 through local media and contacts with community physicians.</recruitment_details>
      <pre_assignment_details>38 women were deemed ineligible. Of those exclusion criteria applied to 27 and 11 declined participation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>This group will receive 5 mg. capsules to be taken once daily.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>These women received placebo capsules identical in appearance and weight to the 5 mg. mifepristone capsule to be taken once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mifepristone 5 mg.</title>
          <description>Twenty-two women received 5 mg. mifepristone daily.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Twenty women received a placebo pill daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.8" spread="6.2"/>
                    <measurement group_id="B2" value="43.2" spread="4.7"/>
                    <measurement group_id="B3" value="43.0" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Uterine Volume</title>
        <description>Uterine volume is measured in mLs</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>This group will receive 5 mg. capsules to be taken once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>These women received placebo capsules identical in appearance and weight to the 5 mg. mifepristone capsule to be taken once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Uterine Volume</title>
          <description>Uterine volume is measured in mLs</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="719" spread="663"/>
                    <measurement group_id="O2" value="449" spread="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>This group will receive 5 mg. capsules to be taken once daily.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>These women received placebo capsules identical in appearance and weight to the 5 mg. mifepristone capsule to be taken once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no adverse events in this clinical trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kevin Fiscella</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-271-1206 ext 205</phone>
      <email>kevin_fiscella@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

